catechin has been researched along with Parkinson Disease in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (13.95) | 29.6817 |
| 2010's | 22 (51.16) | 24.3611 |
| 2020's | 15 (34.88) | 2.80 |
| Authors | Studies |
|---|---|
| Becer, E; Özduran, G; Vatansever, HS; Yücecan, S | 1 |
| Sergi, CM | 1 |
| Chen, J; Chen, Y; Yu, H; Zhao, J; Zheng, Y; Zhu, J | 1 |
| Grønnemose, AL; Jørgensen, TJD; Otzen, DE; Østerlund, EC | 1 |
| Li, X; Tang, Y; Wei, G; Yang, Z; Yao, Y; Zhou, Y | 1 |
| Cordeiro, Y; Gonçalves, PB; Palhano, FL; Sodero, ACR | 1 |
| Chakkittukandiyil, A; Kothandan, R; Rymbai, E; Selvaraj, D; Selvaraj, J; Sugumar, D | 1 |
| Ding, L; Ding, Y; Teng, Y; Zhao, J; Zhou, P | 1 |
| Li, Y; Wang, HL; Xiang, L; Xiao, G; Xiao, J; Xie, M; Xu, Y; Xue, J | 1 |
| Bolakhrif, N; Buell, AK; Haas, R; Peduzzo, A; Sternke-Hoffmann, R | 1 |
| Cima-Omori, MS; Dominguez-Meijide, A; Griesinger, C; Ibáñez de Opakua, A; König, A; Leonov, A; Outeiro, TF; Ryazanov, S; Vasili, E; Zweckstetter, M | 1 |
| Tang, Y; Wei, G; Yao, Y | 1 |
| Kuo, YC; Rajesh, R; Wang, IH | 1 |
| Cui, Y; Du, L; Huang, M; Luo, S; Ma, Q; Sun, X | 1 |
| Cordeiro, Y; Gonçalves, PB; Sodero, ACR | 1 |
| Jovcevski, B; Marty, MT; Pukala, TL; Sanders, HM | 1 |
| Bhak, G; Lee, JT; Lee, S; Paik, SR; Park, JH; Rhoo, KY; Yang, JE | 1 |
| Liang, Z; Zhou, T; Zhu, M | 1 |
| Jung, UJ; Kim, SR | 1 |
| Miyoshi, N; Nakamura, Y; Ohishi, T; Pervin, M; Tanabe, H; Unno, K | 1 |
| Abbasabadi, Z; Bahramsoltani, R; Braidy, N; Farzaei, MH; Nabavi, SM | 1 |
| Chen, Z; Jiang, Z; Li, Y; Liu, L; Lu, Z; Qing, H; Yang, Q; Zhang, L; Zhang, X | 1 |
| Cerboni, L; De Palma, A; Grandori, R; Konijnenberg, A; Legname, G; Mauri, P; Moons, R; Narkiewicz, J; Natalello, A; Ponzini, E; Rossi, R; Santambrogio, C; Sobott, F | 1 |
| Jyoti, S; Naz, F; Siddique, YH | 1 |
| Daglia, M; Martinoli, MG; Nabavi, SF; Nabavi, SM; Renaud, J | 1 |
| Caruana, M; Vassallo, N | 1 |
| Aliev, G; Ávila-Rodriguez, M; Barreto, GE; Echeverria, V; Gonzalez, J; Hidalgo, OA; Jurado-Coronel, JC | 1 |
| Alhussen, F; Azam, F; Mohamed, N | 1 |
| Basil, AH; Hang, L; Lim, KL | 1 |
| Khan, ZA; Mandal, AK; Singh, NA | 1 |
| Dai, R; Guo, J; McGeer, PL; Qing, H; Quan, Z; Wong, W; Xu, Y; Yang, Q; Zhang, R; Zhang, Y | 1 |
| Batra, R; Chowdhury, PK; Gautam, S; Karmakar, S; Kundu, B; Pradhan, P; Sharma, P; Singh, J | 1 |
| Amit, T; Mandel, SA; Reznichenko, L; Weinreb, O; Youdim, MB | 1 |
| Chan, TH; Chang, RC; Chao, J; Ho, YS; Huie, MJ; Lai, CS; Lam, WH; Lau, WK; Wang, M; Yu, MS; Yuen, WH | 1 |
| Chaurasiya, ND; Joshi, VC; Khan, IA; Khan, SI; Miller, LS; Muhammad, I; Rahman, MM; Samoylenko, V; Tekwani, BL; Tripathi, LM; Wang, YH; Wigger, FT | 1 |
| Bae, SY; Hwang, H; Kim, HK; Kim, JH; Kim, S; Kim, TD; Lee, S; Yoon, HC | 1 |
| Chen, RZ; Ruan, HL; Wang, XL; Yang, Y; Zhu, XN | 1 |
| Chen, X; Huang, B; Xu, X; Ye, L; Ye, Q; Zhang, X; Zhu, Y | 1 |
| Amit, T; Mandel, S; Weinreb, O; Youdim, MB | 1 |
| Choi, BH; Ha, H; Kim, DC; Kim, KT; Lee, SJ | 1 |
| Du, F; Le, WD; Li, R; Li, XP; Peng, N | 1 |
| Aruoma, OI; Fujii, H; Nishioka, H; Sun, B; Tomobe, K | 1 |
| Chung, WG; Maier, CS; Miranda, CL | 1 |
11 review(s) available for catechin and Parkinson Disease
| Article | Year |
|---|---|
Epigallocatechin gallate for Parkinson's disease.
Topics: Animals; Catechin; Humans; Neuroprotective Agents; Parkinson Disease; Tea | 2022 |
Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases.
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Protein Precursor; Catechin; Drug Discovery; Humans; Molecular Targeted Therapy; Neurodegenerative Diseases; Parkinson Disease; Protein Aggregates; Protein Folding; Tea | 2021 |
Beneficial Effects of Flavonoids Against Parkinson's Disease.
Topics: Animals; Anthocyanins; Antioxidants; Antiparkinson Agents; Catechin; Cell Line; Corpus Striatum; Disease Models, Animal; Dopamine; Flavanones; Flavones; Flavonoids; Flavonols; Humans; Isoflavones; Kaempferols; Neuroprotective Agents; Oxidative Stress; Parkinson Disease | 2018 |
Beneficial Effects of Green Tea Catechins on Neurodegenerative Diseases.
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Camellia sinensis; Catechin; Cerebral Cortex; Humans; Molecular Docking Simulation; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Tea | 2018 |
Role of green tea catechins in prevention of age-related cognitive decline: Pharmacological targets and clinical perspective.
Topics: Aging; Alzheimer Disease; Animals; Antioxidants; Apoptosis; Catechin; Cognitive Dysfunction; Humans; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Tea | 2019 |
Epigallocatechin-3-Gallate, a Promising Molecule for Parkinson's Disease?
Topics: Catechin; Humans; Parkinson Disease; Prognosis | 2015 |
Tea Polyphenols in Parkinson's Disease.
Topics: alpha-Synuclein; Antioxidants; Biflavonoids; Catechin; Humans; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Polyphenols; Tea | 2015 |
Nutraceuticals in Parkinson's Disease.
Topics: Catechin; Dietary Supplements; Humans; Neuroprotective Agents; Parkinson Disease | 2016 |
Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG).
Topics: Alzheimer Disease; Animals; Antioxidants; Catechin; Humans; Lipid Peroxidation; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Polyphenols; Reproducibility of Results; Signal Transduction; Tea | 2016 |
Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antioxidants; Brain; Catechin; Cells, Cultured; Humans; Hypoxia-Inducible Factor 1; Iron; Neuroprotective Agents; Parkinson Disease; Protein Kinase C | 2008 |
Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases.
Topics: Alzheimer Disease; Animals; Antioxidants; Apoptosis; Catechin; Dietary Supplements; Disease Models, Animal; Flavonoids; Gene Expression Regulation; Humans; Iron Chelating Agents; Neuroprotective Agents; Parkinson Disease; Phenols; Polyphenols; Signal Transduction; Tea | 2004 |
32 other study(ies) available for catechin and Parkinson Disease
| Article | Year |
|---|---|
Neuroprotective effects of catechins in an experimental Parkinson's disease model and SK-N-AS cells: evaluation of cell viability, anti-inflammatory and anti-apoptotic effects.
Topics: Anti-Inflammatory Agents; Apoptosis; Catechin; Cell Survival; Dopamine; Humans; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Tumor Necrosis Factor Inhibitors | 2022 |
The Relationship between Procyanidin Structure and Their Protective Effect in a Parkinson's Disease Model.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Biflavonoids; Catechin; Oxidative Stress; Parkinson Disease; Proanthocyanidins; Rats; Selegiline; Zebrafish | 2022 |
EGCG has Dual and Opposing Effects on the N-terminal Region of Self-associating α-synuclein Oligomers.
Topics: alpha-Synuclein; Catechin; Humans; Oxidation-Reduction; Parkinson Disease; Protein Conformation; Protein Folding | 2022 |
EGCG attenuates α-synuclein protofibril-membrane interactions and disrupts the protofibril.
Topics: alpha-Synuclein; Catechin; Humans; Membranes; Parkinson Disease | 2023 |
How oxidized EGCG remodels α-synuclein fibrils into non-toxic aggregates: insights from computational simulations.
Topics: alpha-Synuclein; Amyloid; Amyloidogenic Proteins; Catechin; Humans; Parkinson Disease; Protein Aggregates | 2023 |
The identification of cianidanol as a selective estrogen receptor beta agonist and evaluation of its neuroprotective effects on Parkinson's disease models.
Topics: Animals; Catechin; Disease Models, Animal; Estrogen Receptor beta; Estrogens; Humans; Neuroblastoma; Neuroprotective Agents; Parkinson Disease; Rats; Rotenone | 2023 |
Complex of EGCG with Cu(II) Suppresses Amyloid Aggregation and Cu(II)-Induced Cytotoxicity of α-Synuclein.
Topics: alpha-Synuclein; Amyloidogenic Proteins; Animals; Catechin; Cell Line; Copper; Neuroprotective Agents; Nuclear Magnetic Resonance, Biomolecular; Oxidative Stress; Parkinson Disease; Protein Aggregates; Protein Aggregation, Pathological; Rats; Reactive Oxygen Species | 2019 |
EGCG ameliorates neuronal and behavioral defects by remodeling gut microbiota and TotM expression in Drosophila models of Parkinson's disease.
Topics: Animals; Behavior, Animal; Catechin; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; Female; Gastrointestinal Microbiome; Heat-Shock Proteins; Male; Mitochondria; Neuroprotective Agents; Parkinson Disease | 2020 |
The Aggregation Conditions Define Whether EGCG is an Inhibitor or Enhancer of
Topics: alpha-Synuclein; Amyloid; Catechin; Humans; Parkinson Disease; Protein Aggregates; Protein Aggregation, Pathological | 2020 |
Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization.
Topics: alpha-Synuclein; Alzheimer Disease; Benzodioxoles; Benzopyrans; Brain; Catechin; Cells, Cultured; Humans; Hydrazones; Lewy Bodies; Molecular Targeted Therapy; Neurofibrillary Tangles; Parkinson Disease; Protein Aggregates; Protein Aggregation, Pathological; Pyrazoles; tau Proteins | 2020 |
Epigallocatechin Gallate Destabilizes α-Synuclein Fibril by Disrupting the E46-K80 Salt-Bridge and Inter-protofibril Interface.
Topics: alpha-Synuclein; Catechin; Humans; Lewy Bodies; Parkinson Disease | 2020 |
Use of leptin-conjugated phosphatidic acid liposomes with resveratrol and epigallocatechin gallate to protect dopaminergic neurons against apoptosis for Parkinson's disease therapy.
Topics: Apoptosis; Catechin; Dopaminergic Neurons; Humans; Leptin; Liposomes; Parkinson Disease; Phosphatidic Acids; Resveratrol | 2021 |
Enhanced Neuroprotective Effects of Epicatechin Gallate Encapsulated by Bovine Milk-Derived Exosomes against Parkinson's Disease through Antiapoptosis and Antimitophagy.
Topics: Animals; Apoptosis; Catechin; Cattle; Exosomes; Milk; Neuroprotective Agents; Parkinson Disease | 2021 |
Structural and mechanistic insights into amyloid-β and α-synuclein fibril formation and polyphenol inhibitor efficacy in phospholipid bilayers.
Topics: alpha-Synuclein; Amyloid; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloidogenic Proteins; Catechin; Humans; Lipid Bilayers; Membrane Lipids; Parkinson Disease; Phospholipids; Polyphenols | 2022 |
EGCG-mediated Protection of the Membrane Disruption and Cytotoxicity Caused by the 'Active Oligomer' of α-Synuclein.
Topics: alpha-Synuclein; Amyloid; Animals; Catechin; Cell Membrane; Disease Models, Animal; Drosophila melanogaster; Electrophoresis, Polyacrylamide Gel; Microscopy, Electron, Transmission; Parkinson Disease | 2017 |
(-)-Epigallocatechin-3-gallate modulates peripheral immunity in the MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catechin; Disease Models, Animal; Dopaminergic Neurons; Immunomodulation; Male; Mice; Neuroprotective Agents; Parkinson Disease; T-Lymphocyte Subsets; Tyrosine 3-Monooxygenase | 2018 |
"Cell-addictive" dual-target traceable nanodrug for Parkinson's disease treatment via flotillins pathway.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Catechin; Cell Line; Disease Models, Animal; Dopaminergic Neurons; Drug Carriers; Humans; Membrane Proteins; Mice; Molecular Targeted Therapy; Nanoparticles; Neuroprotective Agents; Parkinson Disease; Protein Aggregation, Pathological; Treatment Outcome | 2018 |
Methionine oxidation in α-synuclein inhibits its propensity for ordered secondary structure.
Topics: alpha-Synuclein; Catechin; Humans; Lewy Bodies; Methionine; Oxidation-Reduction; Parkinson Disease; Protein Aggregates; Protein Folding; Protein Structure, Secondary; Protein Structure, Tertiary | 2019 |
Effect of epicatechin gallate dietary supplementation on transgenic Drosophila model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Antioxidants; Apoptosis; Brain; Camellia sinensis; Catechin; Dietary Supplements; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Drosophila melanogaster; Drosophila Proteins; Humans; Lipid Peroxidation; Locomotion; Oxidative Stress; Parkinson Disease; Phytotherapy; Plant Extracts | 2014 |
Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease.
Topics: Animals; Catechin; Humans; Neuroprotective Agents; Parkinson Disease; Tea | 2016 |
Molecular interaction studies of green tea catechins as multitarget drug candidates for the treatment of Parkinson's disease: computational and structural insights.
Topics: Catechin; Computational Biology; Drug Delivery Systems; Humans; Molecular Docking Simulation; Parkinson Disease; Protein Binding; Protein Structure, Secondary; Structure-Activity Relationship; Tea | 2015 |
Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson's Disease.
Topics: alpha-Synuclein; Catechin; Cells, Cultured; Humans; Lewy Bodies; Parkinson Disease | 2016 |
Polyphenols in combination with β-cyclodextrin can inhibit and disaggregate α-synuclein amyloids under cell mimicking conditions: A promising therapeutic alternative.
Topics: alpha-Synuclein; Amyloid; Amyloidogenic Proteins; Animals; beta-Cyclodextrins; Catechin; Cell Line; Cell Survival; Circular Dichroism; Curcumin; Humans; Mice; Parkinson Disease; Polyphenols; Protein Aggregation, Pathological | 2017 |
A pro-drug of the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) prevents differentiated SH-SY5Y cells from toxicity induced by 6-hydroxydopamine.
Topics: Caspase 3; Catechin; Cell Line, Tumor; Central Nervous System Agents; Dose-Response Relationship, Drug; Humans; L-Lactate Dehydrogenase; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Time Factors; Tretinoin | 2010 |
Composition, standardization and chemical profiling of Banisteriopsis caapi, a plant for the treatment of neurodegenerative disorders relevant to Parkinson's disease.
Topics: Alkaloids; Animals; Banisteriopsis; Beverages; Biflavonoids; Catechin; Ethnopharmacology; Harmaline; Harmine; Humans; Monoamine Oxidase; Neurodegenerative Diseases; Parkinson Disease; Plant Leaves; Plant Stems; Plants; Proanthocyanidins; Reference Standards; Superoxide Dismutase | 2010 |
Amyloid formation and disaggregation of α-synuclein and its tandem repeat (α-TR).
Topics: alpha-Synuclein; Amyloid; Benzothiazoles; Catechin; Flavanones; Humans; Imidazoles; Imides; Ionic Liquids; Microscopy, Electron, Transmission; Parkinson Disease; Sulfonamides; Tandem Repeat Sequences; Thiazoles | 2010 |
Similar potency of catechin and its enantiomers in alleviating 1-methyl-4-phenylpyridinium ion cytotoxicity in SH-SY5Y cells.
Topics: 1-Methyl-4-phenylpyridinium; Apoptosis; Catechin; Cell Line, Tumor; Humans; L-Lactate Dehydrogenase; MAP Kinase Signaling System; MPTP Poisoning; Oxidative Stress; Parkinson Disease; Phosphorylation; Proto-Oncogene Proteins c-jun; Reactive Oxygen Species | 2011 |
Epigallocatechin-3-gallate suppresses 1-methyl-4-phenyl-pyridine-induced oxidative stress in PC12 cells via the SIRT1/PGC-1α signaling pathway.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antioxidants; Camellia sinensis; Catechin; Cell Survival; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Oxidative Stress; Parkinson Disease; PC12 Cells; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phytotherapy; Plant Extracts; Rats; Reactive Oxygen Species; RNA-Binding Proteins; RNA, Messenger; Signal Transduction; Sirtuin 1; Superoxide Dismutase; Superoxide Dismutase-1; Tea; Transcription Factors; Up-Regulation | 2012 |
Regulation of p53 by activated protein kinase C-delta during nitric oxide-induced dopaminergic cell death.
Topics: Animals; Apoptosis; Catechin; Cell Death; Cell Line; Cell Survival; Coculture Techniques; Dopamine; Enzyme Activation; Immunoblotting; Immunohistochemistry; Immunoprecipitation; In Situ Nick-End Labeling; Mice; Microglia; Models, Biological; Nitric Oxide; Nitrites; Nitroprusside; Parkinson Disease; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase C-delta; Proto-Oncogene Proteins c-mdm2; Serine; Time Factors; Tumor Suppressor Protein p53 | 2006 |
Epigallocatechin gallate protects dopaminergic neurons against 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by inhibiting microglial cell activation.
Topics: Animals; Catechin; Dopamine; Male; Mesencephalon; Mice; Mice, Inbred C57BL; MPTP Poisoning; Neuroglia; Neurons; Neuroprotective Agents; Parkinson Disease; Substantia Nigra; Tea | 2006 |
Modulation of infection-induced inflammation and locomotive deficit and longevity in senescence-accelerated mice-prone (SAMP8) model by the oligomerized polyphenol Oligonol.
Topics: Aging; Alzheimer Disease; Animals; Behavior, Animal; Catechin; Dietary Supplements; Disease Models, Animal; Eye; Female; Inflammation; Longevity; Male; Mice; Mice, Inbred Strains; Motor Activity; Parasitic Diseases, Animal; Parkinson Disease; Phenols; Survival Rate; Time Factors; Virus Diseases | 2007 |
Epigallocatechin gallate (EGCG) potentiates the cytotoxicity of rotenone in neuroblastoma SH-SY5Y cells.
Topics: Antioxidants; Brain; Catechin; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Humans; Insecticides; Neuroblastoma; Neurons; Oxidative Stress; Parkinson Disease; Reactive Oxygen Species; Rotenone; Superoxides | 2007 |